This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LoRusso, P. M. Articles by Burris, H. A. Search for Related Content PubMed PubMed Citation Articles by LoRusso, P. M. Articles by Burris, H. A., III Related Articles Related Correspondence Social Bookmarking                            What's this?

Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer

Patricia M. LoRusso, Suzanne F. Jones, Kevin M. Koch, Nikita Arya, Ronald A. Fleming, Jill Loftiss, Lini Pandite, Shirish Gadgeel, Barbara L. Weber, Howard A. Burris, III

From the Karmanos Cancer Institute, Wayne State University, Detroit, MI; Sarah Cannon Research Institute, Nashville, TN; and GlaxoSmithKline, Research Triangle Park, NC

Corresponding author: Patricia M. LoRusso, DO, Division of Hematology-Oncology, 4100 John R 4HWCRC, Detroit, MI 48201; e-mail: lorussop{at}karmonos.org

Purpose This phase I study assessed the safety, optimally tolerated regimen (OTR), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of lapatinib and docetaxel in patients with advanced solid tumors.

Patients and Methods Doses of lapatinib (oral once daily, continuous) and docetaxel (intravenous, every 3 weeks) were escalated in cohorts of at least three patients based on dose-limiting toxicities in the first treatment cycle until the OTR was reached. The protocol was amended to include pegfilgrastim because of dose-limiting toxicity (neutropenia), and a second dose-escalation phase was conducted to determine the OTR for the combination of docetaxel, lapatinib, and pegfilgrastim. After the determination of the OTR, the pharmacokinetics of lapatinib and docetaxel were determined to estimate the potential for an interaction between docetaxel and lapatinib at the OTR dose level.

Results Fifty-two patients with advanced solid tumors were enrolled. The OTR dose level for lapatinib and docetaxel with pegfilgrastim was 1,250 mg (once daily) and 75 mg/m² (once every 3 weeks), respectively. Overall, adverse events (AEs) were mild to moderate in severity. The drug-related AEs reported by most patients ( 25%) were diarrhea (56%), rash (52%), fatigue (27%), and nausea (25%). Of 43 patients assessable for clinical response, two patients had confirmed partial responses. The pharmacokinetics of lapatinib (area under the curve, maximum serum concentration) and docetaxel (area under the curve, clearance) in combination were not significantly different than when the drugs are administered separately.

Conclusion The combination of docetaxel and lapatinib with pegfilgrastim was well tolerated. No pharmacokinetic interaction was observed. Clinical activity was seen in this phase I drug combination trial.

Supported by a grant from GlaxoSmithKline.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• How Should We Prescribe Lapatinib to Our Patients: Once Daily or Twice Daily, and at What Dose?
  Mariangela Ciccarese and Vito Lorusso
  JCO 2009 27: 314-315 [Full Text]

This article has been cited by other articles:

				A. J. Chien, J. A. Illi, A. H. Ko, W. M. Korn, L. Fong, L.-m. Chen, M. Kashani-Sabet, C. J. Ryan, J. E. Rosenberg, S. Dubey, et al. A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies Clin. Cancer Res., September 1, 2009; 15(17): 5569 - 5575. [Abstract] [Full Text] [PDF]

				L. Horn and A. Sandler Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2009; 15(16): 5040 - 5048. [Abstract] [Full Text] [PDF]

				M. Ciccarese and V. Lorusso How Should We Prescribe Lapatinib to Our Patients: Once Daily or Twice Daily, and at What Dose? J. Clin. Oncol., January 10, 2009; 27(2): 314 - 315. [Full Text] [PDF]

				P. M. LoRusso, H. A. Burris III, S. F. Jones, R. A. Fleming, and K. M. Koch In Reply J. Clin. Oncol., January 10, 2009; 27(2): 316 - 317. [Full Text] [PDF]